+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Atopic Dermatitis Clinical Trials Market Size, Share & Trends Analysis Report by Molecule Type (Small molecules, Large Molecules), Study Designs, Study Phase, Region, and Segment Forecasts, 2024-2030

  • PDF Icon

    Report

  • 125 Pages
  • January 2024
  • Region: Global
  • Grand View Research
  • ID: 5936578
Description Jump to:
The global atopic dermatitis clinical trials market is expected to reach USD 4.84 billion by 2030 and expand at a CAGR of 11.1% from 2024 to 2030. Advancements in biotechnology and medicine, growing prevalence of atopic dermatitis, increasing investments by pharmaceutical companies in the development of novel drugs, rising partnerships and acquisitions among CROs and sponsor companies, technological advancements in clinical research, growing pipeline of atopic dermatitis products, and globalization of clinical trials are few of the factors supporting the lucrative growth of the global market during the forecast period.

For pharmaceutical companies, innovation and easy access to clinics are critical factors. Furthermore, pharmaceutical and biopharmaceutical companies increasingly focus on developing novel drugs for treating atopic dermatitis. For instance, the U.S. FDA stated that several potential therapeutics will be launched in the coming years to treat atopic dermatitis. A few of the potential biologics likely to enter the market include Rocatinlimab by -Kyowa Kirin Co., Ltd., lebrikizumab by Eli Lilly and Company, CM310 by Keymed Biosciences, tozorakimab by AstraZeneca and several others. Hence, the increasing pipeline of therapeutics is one of the major factors augmenting market growth.

Furthermore, the increasing prevalence of atopic dermatitis is a significant catalyst propelling the market growth. Atopic dermatitis is a chronic inflammatory skin condition that has witnessed a notable rise in incidence globally, affecting individuals of all ages. In 2022, approximately 223 million individuals are coping with atopic dermatitis, per the Global Burden of Disease (GBD) 2022 report. Among them, approximately 43 million falls within the age group of 1 to 4 years. This surge in prevalence has created a compelling need for more effective and targeted treatment options. As a result, pharmaceutical companies, research institutions, and healthcare organizations are increasingly investing in clinical trials to explore novel therapeutic interventions.

Moreover, several companies are focusing on inorganic strategic initiatives such as mergers and acquisitions to enhance their position in the industry. For instance, in March 2022, Pfizer Inc. announced the acquisition of Arena Pharmaceuticals, a clinical-stage company dedicated to developing innovative potential therapies for various immuno-inflammatory diseases, including atopic dermatitis.

Atopic Dermatitis Clinical Trials Market Report Highlights

  • Large molecules dominated the molecule type segment with a 53.2% share in 2023 due to the increasing pipeline of biologics penetrating the atopic dermatitis clinical trials industry.
  • Interventional trials dominated the market owing to the large number of clinical trials with interventional study designs.
  • Phase III category by phase segment is anticipated to hold the highest market share in 2023. This is due to the increasing number of drugs undergoing phase III studies. Moreover, the cost of phase III studies is much higher than the other phases, contributing to the largest market share.
  • North America dominated the market owing to factors such as increasing the prevalence of atopic dermatitis in the region, presence of major market players in the region, government support for quality healthcare, and availability of reimbursement.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Details of Primary Research
1.5.1. Data for Primary Interviews in North America
1.5.2. Data for Primary Interviews in Europe
1.5.3. Data for Primary Interviews in Asia-Pacific
1.5.4. Data for Primary Interviews in Latin America
1.5.5. Data for Primary Interviews in MEA
1.6. Information or Data Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Validation
1.8. Model Details
1.8.1. Commodity flow analysis (Model 1)
1.8.2. Approach 1: Commodity flow approach
1.8.3. Parent Market Analysis (Model 2)
1.8.4. Approach 2: Parent Market Analysis
1.9. List of Secondary Sources
1.10. List of Primary Sources
1.11. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Atopic Dermatitis Clinical Trials Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of atopic dermatitis
3.2.1.2. Growing pipeline of therapeutics
3.2.1.3. Increasing funding and investments
3.2.2. market restraint analysis
3.2.2.1. High cost of clinical trials
3.2.2.2. Issues in patient recruitment and retention
3.3. Atopic Dermatitis Clinical Trials Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Atopic Dermatitis Clinical Trials Market: Molecule Type Estimates & Trend Analysis
4.1. Molecule Type Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Atopic Dermatitis Clinical Trials Market by Molecule Type Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Small molecules
4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Large Molecules
4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 5. Atopic Dermatitis Clinical Trials Market: Study Designs Estimates & Trend Analysis
5.1. Study Designs Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Atopic Dermatitis Clinical Trials Market by Study Designs Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Interventional
5.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Observational
5.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 6. Atopic Dermatitis Clinical Trials Market: Phase Estimates & Trend Analysis
6.1. Phase Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Atopic Dermatitis Clinical Trials Market by Phase Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Phase I
6.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Phase II
6.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Phase III
6.4.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Phase IV
6.4.4.1. Market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 7. Atopic Dermatitis Clinical Trials Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2023 & 2030
7.2. Regional Market Dashboard
7.3. Global Regional Market Snapshot
7.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
7.5. North America
7.5.1. U.S.
7.5.1.1. Key country dynamics
7.5.1.2. Regulatory framework
7.5.1.3. Competitive scenario
7.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
7.5.2. Canada
7.5.2.1. Key country dynamics
7.5.2.2. Regulatory framework
7.5.2.3. Competitive scenario
7.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
7.6. Europe
7.6.1. UK
7.6.1.1. Key country dynamics
7.6.1.2. Regulatory framework
7.6.1.3. Competitive scenario
7.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
7.6.2. Germany
7.6.2.1. Key country dynamics
7.6.2.2. Regulatory framework
7.6.2.3. Competitive scenario
7.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
7.6.3. France
7.6.3.1. Key country dynamics
7.6.3.2. Regulatory framework
7.6.3.3. Competitive scenario
7.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
7.6.4. Italy
7.6.4.1. Key country dynamics
7.6.4.2. Regulatory framework
7.6.4.3. Competitive scenario
7.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
7.6.5. Spain
7.6.5.1. Key country dynamics
7.6.5.2. Regulatory framework
7.6.5.3. Competitive scenario
7.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
7.6.6. Denmark
7.6.6.1. Key country dynamics
7.6.6.2. Regulatory framework
7.6.6.3. Competitive scenario
7.6.6.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
7.6.7. Sweden
7.6.7.1. Key country dynamics
7.6.7.2. Regulatory framework
7.6.7.3. Competitive scenario
7.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
7.6.8. Norway
7.6.8.1. Key country dynamics
7.6.8.2. Regulatory framework
7.6.8.3. Competitive scenario
7.6.8.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
7.7. Asia-Pacific
7.7.1. Japan
7.7.1.1. Key country dynamics
7.7.1.2. Regulatory framework
7.7.1.3. Competitive scenario
7.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
7.7.2. China
7.7.2.1. Key country dynamics
7.7.2.2. Regulatory framework
7.7.2.3. Competitive scenario
7.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
7.7.3. India
7.7.3.1. Key country dynamics
7.7.3.2. Regulatory framework
7.7.3.3. Competitive scenario
7.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
7.7.4. Australia
7.7.4.1. Key country dynamics
7.7.4.2. Regulatory framework
7.7.4.3. Competitive scenario
7.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
7.7.5. Thailand
7.7.5.1. Key country dynamics
7.7.5.2. Regulatory framework
7.7.5.3. Competitive scenario
7.7.5.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
7.7.6. South Korea
7.7.6.1. Key country dynamics
7.7.6.2. Regulatory framework
7.7.6.3. Competitive scenario
7.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
7.8. Latin America
7.8.1. Brazil
7.8.1.1. Key country dynamics
7.8.1.2. Regulatory framework
7.8.1.3. Competitive scenario
7.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
7.8.2. Mexico
7.8.2.1. Key country dynamics
7.8.2.2. Regulatory framework
7.8.2.3. Competitive scenario
7.8.2.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
7.8.3. Argentina
7.8.3.1. Key country dynamics
7.8.3.2. Regulatory framework
7.8.3.3. Competitive scenario
7.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
7.9. MEA
7.9.1. South Africa
7.9.1.1. Key country dynamics
7.9.1.2. Regulatory framework
7.9.1.3. Competitive scenario
7.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
7.9.2. Saudi Arabia
7.9.2.1. Key country dynamics
7.9.2.2. Regulatory framework
7.9.2.3. Competitive scenario
7.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
7.9.3. UAE
7.9.3.1. Key country dynamics
7.9.3.2. Regulatory framework
7.9.3.3. Competitive scenario
7.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
7.9.4. Kuwait
7.9.4.1. Key country dynamics
7.9.4.2. Regulatory framework
7.9.4.3. Competitive scenario
7.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Company/Competition Categorization
8.1.1. Innovators
8.1.2. Market Leaders
8.1.3. Emerging Players
8.1.4. Company Market Share Analysis, 2023
8.2. Company Profiles
8.2.1. Charles River Laboratories
8.2.1.1. Company overview
8.2.1.2. Financial performance
8.2.1.3. Product benchmarking
8.2.1.4. Strategic initiatives
8.2.2. Imavita
8.2.2.1. Company overview
8.2.2.2. Financial performance
8.2.2.3. Product benchmarking
8.2.2.4. Strategic initiatives
8.2.3. REPROCELL Inc.
8.2.3.1. Company overview
8.2.3.2. Financial performance
8.2.3.3. Product benchmarking
8.2.3.4. Strategic initiatives
8.2.4. Oncodesign services
8.2.4.1. Company overview
8.2.4.2. Financial performance
8.2.4.3. Product benchmarking
8.2.4.4. Strategic initiatives
8.2.5. BIOCYTOGEN
8.2.5.1. Company overview
8.2.5.2. Financial performance
8.2.5.3. Product benchmarking
8.2.5.4. Strategic initiatives
8.2.6. QIMA LTD
8.2.6.1. Company overview
8.2.6.2. Financial performance
8.2.6.3. Product benchmarking
8.2.6.4. Strategic initiatives
8.2.7. Novotech
8.2.7.1. Company overview
8.2.7.2. Financial performance
8.2.7.3. Product benchmarking
8.2.7.4. Strategic initiatives
8.2.8. Redoxis
8.2.8.1. Company overview
8.2.8.2. Financial performance
8.2.8.3. Product benchmarking
8.2.8.4. Strategic initiatives
8.2.9. Syneos Health
8.2.9.1. Company overview
8.2.9.2. Financial performance
8.2.9.3. Product benchmarking
8.2.9.4. Strategic initiatives
8.2.10. Hooke Laboratories, LLC
8.2.10.1. Company overview
8.2.10.2. Financial performance
8.2.10.3. Product benchmarking
8.2.10.4. Strategic initiatives
List of Tables
Table 1 List of abbreviation
Table 2 North America Atopic Dermatitis Clinical Trials market, by region, 2018-2030 (USD Million)
Table 3 North America Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 4 North America Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 5 North America Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 6 U.S. Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 7 U.S. Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 8 U.S. Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 9 Canada Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 10 Canada Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 11 Canada Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 12 Europe Atopic Dermatitis Clinical Trials market, by region, 2018-2030 (USD Million)
Table 13 Europe Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 14 Europe Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 15 Europe Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 16 UK Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 17 UK Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 18 UK Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 19 Germany Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 20 Germany Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 21 Germany Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 22 France Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 23 France Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 24 France Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 25 Italy Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 26 Italy Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 27 Italy Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 28 Spain Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 29 Spain Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 30 Spain Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 31 Denmark Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 32 Denmark Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 33 Denmark Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 34 Sweden Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 35 Sweden Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 36 Sweden Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 37 Norway Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 38 Norway Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 39 Norway Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 40 Asia-Pacific Atopic Dermatitis Clinical Trials market, by region, 2018-2030 (USD Million)
Table 41 Asia-Pacific Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 42 Asia-Pacific Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 43 Asia-Pacific Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 44 Japan Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 45 Japan Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 46 Japan Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 47 China Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 48 China Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 49 China Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 50 India Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 51 India Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 52 India Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 53 Australia Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 54 Australia Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 55 Australia Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 56 Thailand Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 57 Thailand Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 58 Thailand Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 59 South Korea Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 60 South Korea Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 61 South Korea Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 62 Latin America Atopic Dermatitis Clinical Trials market, by region, 2018-2030 (USD Million)
Table 63 Latin America Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 64 Latin America Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 65 Latin America Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 66 Brazil Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 67 Brazil Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 68 Brazil Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 69 Mexico Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 70 Mexico Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 71 Mexico Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 72 Argentina Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 73 Argentina Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 74 Argentina Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 75 MEA Atopic Dermatitis Clinical Trials market, by region, 2018-2030 (USD Million)
Table 76 MEA Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 77 MEA Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 78 MEA Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 79 South Africa Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 80 South Africa Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 81 South Africa Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 82 Saudi Arabia Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 83 Saudi Arabia Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 84 Saudi Arabia Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 85 UAE Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 86 UAE Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 87 UAE Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
Table 88 Kuwait Atopic Dermatitis Clinical Trials market, by molecule type, 2018-2030 (USD Million)
Table 89 Kuwait Atopic Dermatitis Clinical Trials market, by study designs, 2018-2030 (USD Million)
Table 90 Kuwait Atopic Dermatitis Clinical Trials market, by phase, 2018-2030 (USD Million)
List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Primary interviews in North America
Fig. 5 Primary interviews in Europe
Fig. 6 Primary interviews in APAC
Fig. 7 Primary interviews in Latin America
Fig. 8 Primary interviews in MEA
Fig. 9 Market research approaches
Fig. 10 Value-chain-based sizing & forecasting
Fig. 11 QFD modeling for market share assessment
Fig. 12 Market formulation & validation
Fig. 13 Atopic Dermatitis Clinical Trials market: market outlook
Fig. 14 Atopic Dermatitis Clinical Trials competitive insights
Fig. 15 Parent market outlook
Fig. 16 Related/ancillary market outlook
Fig. 17 Penetration and growth prospect mapping
Fig. 18 Industry value chain analysis
Fig. 19 Atopic Dermatitis Clinical Trials market driver impact
Fig. 20 Atopic Dermatitis Clinical Trials market restraint impact
Fig. 21 Atopic Dermatitis Clinical Trials market: Molecule Type movement analysis
Fig. 22 Atopic Dermatitis Clinical Trials market: Molecule Type outlook and key takeaways
Fig. 23 Small molecules market estimates and forecast, 2018-2030
Fig. 24 Large Molecules market estimates and forecast, 2018-2030
Fig. 25 Atopic Dermatitis Clinical Trials Market: Study Designs movement Analysis
Fig. 26 Atopic Dermatitis Clinical Trials market: Study Designs outlook and key takeaways
Fig. 27 Interventional market estimates and forecasts,2018-2030
Fig. 28 Observational market estimates and forecasts,2018-2030
Fig. 29 Atopic Dermatitis Clinical Trials Market: Phase movement Analysis
Fig. 30 Atopic Dermatitis Clinical Trials market: Phase outlook and key takeaways
Fig. 31 Phase I market estimates and forecasts,2018-2030
Fig. 32 Phase II market estimates and forecasts,2018-2030
Fig. 33 Phase III market estimates and forecasts,2018-2030
Fig. 34 Phase IV market estimates and forecasts,2018-2030
Fig. 35 Global Atopic Dermatitis Clinical Trials market: Regional movement analysis
Fig. 36 Global Atopic Dermatitis Clinical Trials market: Regional outlook and key takeaways
Fig. 37 Global Atopic Dermatitis Clinical Trials market share and leading players
Fig. 38 North America market share and leading players
Fig. 39 Europe market share and leading players
Fig. 40 Asia-Pacific market share and leading players
Fig. 41 Latin America market share and leading players
Fig. 42 Middle East & Africa market share and leading players
Fig. 43 North America, by country
Fig. 44 North America
Fig. 45 North America market estimates and forecasts, 2018-2030
Fig. 46 U.S.
Fig. 47 U.S. market estimates and forecasts, 2018-2030
Fig. 48 Canada
Fig. 49 Canada market estimates and forecasts, 2018-2030
Fig. 50 Europe
Fig. 51 Europe market estimates and forecasts, 2018-2030
Fig. 52 UK
Fig. 53 UK market estimates and forecasts, 2018-2030
Fig. 54 Germany
Fig. 55 Germany market estimates and forecasts, 2018-2030
Fig. 56 France
Fig. 57 France market estimates and forecasts, 2018-2030
Fig. 58 Italy
Fig. 59 Italy market estimates and forecasts, 2018-2030
Fig. 60 Spain
Fig. 61 Spain market estimates and forecasts, 2018-2030
Fig. 62 Denmark
Fig. 63 Denmark market estimates and forecasts, 2018-2030
Fig. 64 Sweden
Fig. 65 Sweden market estimates and forecasts, 2018-2030
Fig. 66 Norway
Fig. 67 Norway market estimates and forecasts, 2018-2030
Fig. 68 Asia-Pacific
Fig. 69 Asia-Pacific market estimates and forecasts, 2018-2030
Fig. 70 Japan
Fig. 71 Japan market estimates and forecasts, 2018-2030
Fig. 72 China
Fig. 73 China market estimates and forecasts, 2018-2030
Fig. 74 India
Fig. 75 India market estimates and forecasts, 2018-2030
Fig. 76 Australia
Fig. 77 Australia market estimates and forecasts, 2018-2030
Fig. 78 Thailand
Fig. 79 Thailand market estimates and forecasts, 2018-2030
Fig. 80 South Korea
Fig. 81 South Korea market estimates and forecasts, 2018-2030
Fig. 82 Latin America
Fig. 83 Latin America market estimates and forecasts, 2018-2030
Fig. 84 Brazil
Fig. 85 Brazil market estimates and forecasts, 2018-2030
Fig. 86 Mexico
Fig. 87 Mexico market estimates and forecasts, 2018-2030
Fig. 88 Argentina
Fig. 89 Argentina market estimates and forecasts, 2018-2030
Fig. 90 Middle East and Africa
Fig. 91 Middle East and Africa market estimates and forecasts, 2018-2030
Fig. 92 South Africa
Fig. 93 South Africa market estimates and forecasts, 2018-2030
Fig. 94 Saudi Arabia
Fig. 95 Saudi Arabia market estimates and forecasts, 2018-2030
Fig. 96 UAE
Fig. 97 UAE market estimates and forecasts, 2018-2030
Fig. 98 Kuwait
Fig. 99 Kuwait market estimates and forecasts, 2018-2030
Fig. 100 Market share of key market players- Atopic Dermatitis Clinical Trials market

Companies Mentioned

  • Charles River Laboratories
  • Imavita
  • REPROCELL Inc.
  • Oncodesign services
  • BIOCYTOGEN
  • QIMA LTD
  • Novotech
  • Redoxis
  • Syneos Health
  • Hooke Laboratories, LLC

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages125
PublishedJanuary 2024
Forecast Period2023 - 2030
Estimated Market Value ( USD ) in 2023 $ 2.33 Billion
Forecasted Market Value ( USD ) by 2030 $ 4.84 Billion
Compound Annual Growth Rate11.1%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Atopic Dermatitis Clinical Trials Market Analysis & Forecast to 2024-2034: Market By Phase; By Molecule Type; By Study Design; and By Region - Product Image

Atopic Dermatitis Clinical Trials Market Analysis & Forecast to 2024-2034: Market By Phase; By Molecule Type; By Study Design; and By Region

  • Report
  • 200 Pages
  • Global
From
Moderate to Severe Atopic Dermatitis (AD) - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Moderate to Severe Atopic Dermatitis (AD) - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Moderate to Severe Atopic Dermatitis - Pipeline Insight, 2024 - Product Image

Moderate to Severe Atopic Dermatitis - Pipeline Insight, 2024

  • Clinical Trials
  • 40 Pages
  • Global
From
Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2024 - Product Image

Atopic Dermatitis (Atopic Eczema) - Global Clinical Trials Review, 2024

  • Clinical Trials
  • 1168 Pages
  • Global
From
Atopic Dermatitis Market Report and Forecast 2024-2032 - Product Image

Atopic Dermatitis Market Report and Forecast 2024-2032

  • Report
  • 160 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.